天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Nucleoside drugs>Nucleotides and their analogs>5-Fluorouracil
5-Fluorouracil
  • 5-Fluorouracil
  • 5-Fluorouracil

5-Fluorouracil NEW

Price $5 $0.1
Package 1KG 1000KG
Min. Order: 1KG
Supply Ability: g-kg-tons, free sample is available
Update Time: 2024-04-09

Product Details

Product Name: 5-Fluorouracil CAS No.: 51-21-8
Min. Order: 1KG Purity: 98%
Supply Ability: g-kg-tons, free sample is available Release date: 2024/04/09
Lead time: In stock, ready for shipment Packaging: bag/bottle/drum/IBC
Delivery: By express, by air, by sea Delivery: Manufacturer, advantage product
COA, MSDS: Manufacturer, advantage product Name: Tina

 1. Materials information

Names

Name5-fluorouracil
SynonymMore Synonyms

 Fluorouracil Biological Activity

Description5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.
Related Catalog
Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog
Research Areas >> Cancer
In Vitro5-Fluorouracil (5-Fu) and doxorubicin (Dox) show synergistic anticancer efficacy. The IC50 value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively[1]. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells[3].
In Vivo5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility[2].
Animal AdminMice receive intraperitoneal injections of 5-FU (23 mg/kg), 3 times a week via a 26 gauge needle. 5-FU is dissolved in 100% dimethyl sulfoxide (DMSO) to make 1 M/L stock solution refrigerated at ?20°C. The stock is then defrosted and diluted with sterile water to make 0.1 M/L (10% DMSO) solutions for intraperitoneal injections. The dose of 5-FU is calculated to be equivalent to standard human dose per body surface area. The low doses of 5-FU (10-40 mg/kg) have been shown to have antitumor efficacy in mouse models of cancer. Sham-treated mice received 10% DMSO in sterile water via intraperitoneal injection three times a week via a 26 gauge needle. The injected volumes are calculated to the body weight; the maximum volume does not exceed 200 μL per injection. Mice are euthanized via cervical dislocation at 3 (2 treatments), 7 (3 treatments), and 14 (6 treatments) days after the first injection and colon is collected for in vitro experiments.
References

[1]. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print]

[2]. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28.

[3]. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46.

[4]. Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130.

 Chemical & Physical Properties

Density1.7±0.1 g/cm3
Boiling Point401.4±48.0 °C at 760 mmHg
Melting Point282-286 °C (dec.)(lit.)
Molecular FormulaC4H3FN2O2
Molecular Weight130.077
Flash Point196.5±29.6 °C
Exact Mass130.017853
PSA65.72000
LogP-2.10
Vapour Pressure0.0±1.0 mmHg at 25°C
Index of Refraction1.596
Storage conditionStore at 0-5
StabilityStable. Light sensitive. Combustible. Incompatible with strong oxidizing agents, strong bases.
Water Solubility12.2 g/L 20 oC

 MSDS

Fluorouracil MSDS(Chinese)

 Toxicological Information

CHEMICAL IDENTIFICATION

  • RTECS NUMBER :

  • YR0350000

  • CHEMICAL NAME :

  • Uracil, 5-fluoro-

  • CAS REGISTRY NUMBER :

  • 51-21-8

  • LAST UPDATED :

  • 199710

  • DATA ITEMS CITED :

  • 156

  • MOLECULAR FORMULA :

  • C4-H3-F-N2-O2

  • MOLECULAR WEIGHT :

  • 130.09

  • WISWESSER LINE NOTATION :

  • T6MVMVJ EF

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

  • TYPE OF TEST :

  • Standard Draize test

  • ROUTE OF EXPOSURE :

  • Administration onto the skin

  • SPECIES OBSERVED :

  • Human

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Human

  • DOSE/DURATION :

  • 450 mg/kg/30D

  • TOXIC EFFECTS :

  • Gastrointestinal - other changes Blood - changes in bone marrow (not otherwise specified) Tumorigenic - active as anti-cancer agent

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human

  • DOSE/DURATION :

  • 6 mg/kg/3D

  • TOXIC EFFECTS :

  • Cardiac - EKG changes not diagnostic of specified effects Cardiac - other changes Lungs, Thorax, or Respiration - other changes

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 150 mg/kg/17W-I

  • TOXIC EFFECTS :

  • Blood - other hemolysis with or without anemia

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - man

  • DOSE/DURATION :

  • 39 mg/kg/1D-I

  • TOXIC EFFECTS :

  • Cardiac - changes in coronary arteries

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Human - woman

  • DOSE/DURATION :

  • 27 mg/kg/4D-C

  • TOXIC EFFECTS :

  • Cardiac - other changes

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 230 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 70 mg/kg

  • TOXIC EFFECTS :

  • Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 217 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 245 mg/kg

  • TOXIC EFFECTS :

  • Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 240 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Parenteral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 500 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Rectal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 884 mg/kg

  • TOXIC EFFECTS :

  • Gastrointestinal - hypermotility, diarrhea Gastrointestinal - other changes

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 115 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 100 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 169 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 81 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intracerebral

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 41600 ug/kg

  • TOXIC EFFECTS :

  • Peripheral Nerve and Sensation - sensory change involving peripheral nerve Sense Organs and Special Senses (Eye) - ptosis Sense Organs and Special Senses (Eye) - effect, not otherwise specified

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Intratracheal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 200 mg/kg

  • TOXIC EFFECTS :

  • Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Unreported

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 171 mg/kg

  • TOXIC EFFECTS :

  • Details of toxic effects not reported other than lethal dose value

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 30 mg/kg

  • TOXIC EFFECTS :

  • Gastrointestinal - nausea or vomiting

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 18900 ug/kg

  • TOXIC EFFECTS :

  • Behavioral - muscle weakness Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • LDLo - Lowest published lethal dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - rabbit

  • DOSE/DURATION :

  • 15 mg/kg

  • TOXIC EFFECTS :

  • Vascular - BP elevation not characterized in autonomic section

  • TYPE OF TEST :

  • LD50 - Lethal dose, 50 percent kill

  • ROUTE OF EXPOSURE :

  • Intravenous

  • SPECIES OBSERVED :

  • Rodent - guinea pig

  • DOSE/DURATION :

  • 25 mg/kg

  • TOXIC EFFECTS :

  • Vascular - BP elevation not characterized in autonomic section

  • TYPE OF TEST :

  • LD10 - Lethal Dose

  • ROUTE OF EXPOSURE :

  • Parenteral

  • SPECIES OBSERVED :

  • Rodent - hamster

  • DOSE/DURATION :

  • 140 mg/kg

  • TOXIC EFFECTS :

  • Tumorigenic - active as anti-cancer agent

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 2520 mg/kg/12W-I

  • TOXIC EFFECTS :

  • Endocrine - changes in spleen weight Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - changes in testicular weight

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1092 mg/kg/30D-I

  • TOXIC EFFECTS :

  • Endocrine - changes in thymus weight Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 6552 mg/kg/26W-I

  • TOXIC EFFECTS :

  • Endocrine - changes in thymus weight Liver - changes in liver weight Blood - changes in erythrocyte (RBC) count

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 700 mg/kg/40W-I

  • TOXIC EFFECTS :

  • Nutritional and Gross Metabolic - weight loss or decreased weight gain Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 1283 mg/kg/13W-C

  • TOXIC EFFECTS :

  • Behavioral - fluid intake Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 360 mg/kg/60D-I

  • TOXIC EFFECTS :

  • Related to Chronic Data - death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 780 mg/kg/30D-I

  • TOXIC EFFECTS :

  • Endocrine - changes in thymus weight Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 2340 mg/kg/13W-I

  • TOXIC EFFECTS :

  • Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 21 mg/kg/7D-I

  • TOXIC EFFECTS :

  • Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count Blood - changes in platelet count

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Rectal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 4920 mg/kg/90D-I

  • TOXIC EFFECTS :

  • Gastrointestinal - other changes Endocrine - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Rectal

  • SPECIES OBSERVED :

  • Rodent - rat

  • DOSE/DURATION :

  • 9540 mg/kg/26W-I

  • TOXIC EFFECTS :

  • Gastrointestinal - other changes Endocrine - other changes Related to Chronic Data - death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 300 mg/kg/60D-I

  • TOXIC EFFECTS :

  • Endocrine - changes in spleen weight Related to Chronic Data - death Related to Chronic Data - changes in testicular weight

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 455 mg/kg/13W-I

  • TOXIC EFFECTS :

  • Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • SPECIES OBSERVED :

  • Mammal - dog

  • DOSE/DURATION :

  • 175 mg/kg/5W-I

  • TOXIC EFFECTS :

  • Behavioral - convulsions or effect on seizure threshold Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • SPECIES OBSERVED :

  • Rodent - mouse

  • DOSE/DURATION :

  • 1500 mg/kg/50W-I

  • TOXIC EFFECTS :

  • Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - tumors

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 150 mg/kg

  • SEX/DURATION :

  • female 20-31 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - other neonatal measures or effects

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 240 mg/kg

  • SEX/DURATION :

  • female 11-14 week(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 35 mg/kg

  • SEX/DURATION :

  • female 7-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 175 mg/kg

  • SEX/DURATION :

  • female 7-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 15 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 30 mg/kg

  • SEX/DURATION :

  • female 12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - gastrointestinal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 30 mg/kg

  • SEX/DURATION :

  • female 12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - homeostasis

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 20 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 20 mg/kg

  • SEX/DURATION :

  • female 14 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Subcutaneous

  • DOSE :

  • 30 mg/kg

  • SEX/DURATION :

  • female 14 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 330 mg/kg

  • SEX/DURATION :

  • female 7-17 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 175 mg/kg

  • SEX/DURATION :

  • female 7-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Oral

  • DOSE :

  • 245 mg/kg

  • SEX/DURATION :

  • female 7-13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetal death

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 50 mg/kg

  • SEX/DURATION :

  • female 13 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 20 mg/kg

  • SEX/DURATION :

  • female 10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 20 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 30 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - abortion

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 10 mg/kg

  • SEX/DURATION :

  • female 10 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intraperitoneal

  • DOSE :

  • 30 mg/kg

  • SEX/DURATION :

  • female 12 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intravenous

  • DOSE :

  • 67 mg/kg

  • SEX/DURATION :

  • male 1 day(s) pre-mating

  • TOXIC EFFECTS :

  • Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • DOSE :

  • 24 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • DOSE :

  • 28 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • DOSE :

  • 56 mg/kg

  • SEX/DURATION :

  • female 11 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Specific Developmental Abnormalities - homeostasis

  • TYPE OF TEST :

  • TDLo - Lowest published toxic dose

  • ROUTE OF EXPOSURE :

  • Intramuscular

  • DOSE :

  • 20 mg/kg

  • SEX/DURATION :

  • female 9 day(s) after conception

  • TOXIC EFFECTS :

  • Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

  • TYPE OF TEST :

  • Specific locus test

  • TYPE OF TEST :

  • DNA inhibition

  • TYPE OF TEST :

  • Mutation test systems - not otherwise specified

  • TYPE OF TEST :

  • Mutation test systems - not otherwise specified

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • Mutation test systems - not otherwise specified

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • Unscheduled DNA synthesis

  • TYPE OF TEST :

  • DNA inhibition

  • TYPE OF TEST :

  • Mutation test systems - not otherwise specified

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Cytogenetic analysis

  • TYPE OF TEST :

  • Sperm Morphology

  • TYPE OF TEST :

  • Sperm Morphology

  • TYPE OF TEST :

  • Micronucleus test

  • TYPE OF TEST :

  • Cytogenetic analysis

MUTATION DATA

  • TYPE OF TEST :

  • DNA inhibition

  • TEST SYSTEM :

  • Mammal - species unspecified Cells - not otherwise specified

  • DOSE/DURATION :

  • 100 umol/L

  • REFERENCE :

  • MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 120,139,1983 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,217,1981 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,217,1981 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,210,1987 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 291,75,1974 TOXICOLOGY REVIEW MIMDAL Minnesota Medicine. (Minnesota Medical Assoc., 2221 University Ave., SE, Suite 400, Minneapolis, MN 55414) V.1- 1918- Volume(issue)/page/year: 57,19,1974 TOXICOLOGY REVIEW JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 172,1765,1960 TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 TOXICOLOGY REVIEW JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 144,429,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4035 No. of Facilities: 681 (estimated) No. of Industries: 2 No. of Occupations: 9 No. of Employees: 23501 (estimated) No. of Female Employees: 15547 (estimated)

 Safety Information

SymbolArticle illustration
GHS06
Signal WordDanger
Hazard StatementsH301-H412
Precautionary StatementsP273-P301 + P310
Hazard CodesXn:Harmful
Risk PhrasesR20/21/22
Safety PhrasesS36-S36/37
RIDADRUN 2811 6.1/PG 3
WGK Germany3
RTECSYR0350000
Packaging GroupIII
Hazard Class6.1
HS Code2933599090

 Synthetic Route

Previous 1/27 Next
Article illustration

cytosine

71-30-7

~79%

Article illustration

Fluorouracil

51-21-8

Literature: Daikin Kogyo Co., Ltd.; Asahi Chemical Industry Co., Ltd. Patent: US4122251 A1, 1978 ;
Article illustration

Uracil

66-22-8

~92%

Article illustration

Fluorouracil

51-21-8

Literature: Yemul, S. S.; Kagan, H. B.; Setton, R. Tetrahedron Letters, 1980 , vol. 21, p. 277 - 280
Article illustration

Cytosine hydroc...

1784-08-3

~64%

Article illustration

Fluorouracil

51-21-8

Literature: Daikin Kogyo Co., Ltd.; Asahi Chemical Industry Co., Ltd. Patent: US4122251 A1, 1978 ;

 Precursor & DownStream

Precursor  9

Previous 1/3 Next

  • Article illustration CAS#:71-30-7
    cytosine

  • Article illustration CAS#:66-22-8
    Uracil

  • Article illustration CAS#:1784-08-3
    Cytosine hydroc...

  • Article illustration CAS#:75500-02-6
    2,4(1H,3H)-Pyri...

DownStream  10

Previous 1/3 Next

  • Article illustration CAS#:105434-88-6
    5-fluoro-1-(4-m...

  • Article illustration CAS#:105411-89-0
    1-(4-butoxyphen...

  • Article illustration CAS#:111854-27-4
    1,3-bis(ethenyl...

  • Article illustration CAS#:72975-39-4
    1-vinyl-5-fluor...

 Customs

HS Code2933599090
Summary2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%



2. Packaging of materials

  • For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.

  • For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product. 

                             Or smaller package 1kg/bottle, 10kgs/bottle as request. 


Article illustrationArticle illustration


3. Shipping & Delivery

  • By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

Article illustration


  • By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

Article illustration


  • By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

Article illustration


4. Contact information

For more details, pls contact us freely.

Email address: Tina@fdachem.com

Mob: 86 13213167925

WhatsApp/Skype/Wechat/LINE: 86 13213167925











Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$48.00/1g
VIP5Y
TargetMol Chemicals Inc.
2024-11-19
$48.00/1g
VIP3Y
TargetMol Chemicals Inc.
2024-11-19
$25.00/1ASSAYS
VIP6Y
Hebei Weibang Biotechnology Co., Ltd
 2024-11-18
$0.00/5Kg
VIP1Y
Xinxiang Aurora Biotechnology Co.,Ltd.
 2024-11-13
$100.00/1kg
VIP4Y
Hebei Chuanghai Biotechnology Co,.LTD
 2024-08-22
$60.00/1kg
VIP1Y
S&Y Biochem Co.,Ltd
 2024-08-01
$0.00/1kg
VIP1Y
Hangzhou Hyper Chemicals Limited
 2024-05-08
$100.00/1kg
Ouhuang Engineering Materials (Hubei) Co., Ltd
 2024-04-22
$0.00/1kg
VIP1Y
Shaanxi TNJONE Pharmaceutical Co., Ltd
 2024-04-15
$9.00/10g
VIP1Y
Hebei Kangcang new material Technology Co., LTD
 2024-03-27
  • Since: 2023-02-10
  • Address: Room 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro
INQUIRY